Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.

Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.

Azathioprine is the most continued treatment for chronic alopecia areata over a year, often with added low-dose prednisolone.

Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.

Upadacitinib effectively treats skin conditions like eczema and psoriasis and is becoming more widely used and affordable.

Dupilumab improves skin microbiome balance in atopic dermatitis patients.

Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

Dupilumab effectively reduces alopecia areata symptoms in children with atopic dermatitis.

Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.

Co-trimoxazole may help treat autoimmune diseases.

Methotrexate is effective for rheumatoid arthritis but can cause side effects.

Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.

IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.

Patients with acute and subacute skin lupus respond faster to belimumab than those with chronic skin lupus.

Belimumab may cause hair loss in lupus patients.

Tofacitinib may help regrow hair in alopecia areata patients.

Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.

Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.

Erenumab significantly reduced migraine days or severity in most patients after 3 months.

Tralokinumab effectively improved atopic dermatitis symptoms in most patients, but some stopped due to side effects like hair loss.

Infliximab was effective in treating a scalp condition that did not respond to other treatments.

Rheumatology clinics should always provide preconception counseling for women on DMARDs.

Low-dose tofacitinib is effective and cheaper for severe alopecia areata.

Ixekizumab is safe for long-term use with low rates of major heart-related events.

Dupilumab for atopic dermatitis may cause new or worsen existing alopecia areata.